β-Peptide Immunization
Open Access
- 1 July 2000
- journal article
- review article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 57 (7) , 934-936
- https://doi.org/10.1001/archneur.57.7.934
Abstract
Research on the pathophysiological characteristics of Alzheimer disease (AD) over the past decade has been directed toward the ultimate goal of developing a disease-modifying treatment to control or prevent the disease. A report recently published in Nature1 describes for the first time a treatment that may both prevent and treat the progression of Alzheimer disease. The treatment ironically involves immunization with the pathological β-amyloid peptide itself to generate an immune response targeted against the amyloid plaques in the brain. These findings have raised a number of scientific and clinical questions that are discussed below.Keywords
This publication has 5 references indexed in Scilit:
- Cellular mechanisms of β-amyloid production and secretionProceedings of the National Academy of Sciences, 1999
- Passage of intravenous immunoglobulin and interaction with the CNS.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- An Increased Percentage of Long Amyloid β Protein Secreted by Familial Amyloid β Protein Precursor (βApp 717 ) MutantsScience, 1994
- Serum Proteins Bypass the Blood-Brain Fluid Barriers for Extracellular Entry to the Central Nervous SystemExperimental Neurology, 1993
- Laboratory Investigation of Cerebrospinal Fluid ProteinsAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1990